Clinical Trials Browser

Lung Neoplasms

Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung

Lung Neoplasms

Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung

Lung Neoplasms

Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung

Lung Neoplasms

Stage IV EGFR Mutated Non-Small Cell Lung Cancer

Lung Neoplasms

Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Carcinoma, Non-Small-Cell Lung

Lung Neoplasms

Carcinoma, Non-Small-Cell Lung

Lung Neoplasms, Neoplasms

Non-Small-Cell Lung

Non-squamous Non-small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung

Non-small Cell Lung Cancer Metastatic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

Adenocarcinoma of Lung, Adenocarcinoma, Bronchiolo-Alveolar, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung

Lung Neoplasms

Carcinoma, Non-Small-Cell Lung, Pleural Effusion, Malignant

Lung Neoplasms, Respiratory Tract Diseases, Thoracic Neoplasms

Adenocarcinoma of Lung

Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Adenocarcinoma of Lung

Adenocarcinoma of Lung, Adenocarcinoma

Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung

Clinical Trials

Therapy for Advanced NSCLC With EGFR 19delins Mutation

Emulation of the FLAURA (NCT02296125) Trial Using Specialty Oncology Electronic Health Records Databases

Osimertinib and Gefitinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer

A Study of EGF816 and Gefitinib in TKI-naïve EGFR-mutant Non-Small Cell Lung Cancer

ZD1839 With Hypofractionated Radiation Therapy With an Immobilization Device for Advanced Non-Small Cell Lung Cancer

Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients

NEGOTIATE

PIKACHU

GOAL

Preoperative Gefitinib for EGFR Mutant II-IIIa NSCLC (ECTOP-1001)

BKM120

Gefitinib With or Without Chemotherapy in Brain Metastases From Non-small Cell Lung Cancer

PROGRESS

IRENE

Sindas

LADIE

BELLA

PD-1 Immune Checkpoint Inhibitors and Immune-Related Adverse Events: a Cohort Study

Gefitinib With Anlotinib in Advanced Non-squamous NSCLC Patients With Uncleared Plasma ctDNA EGFRm After First-line Treatment With Gefitinib

ADJUVANT

Third-line Treatment of Gefitinib in NSCLC Patients

Psychometric Properties of the EORTC QLQ-LC29

FL-ALTER

Anlotinib Hydrochloride Combined With EGFR-Tyrosine Kinase Inhibitor (TKI) in Treating Advanced NSCLC Patients With Acquired Resistance to EGFR-TKI

Clinical Study of Chinese Medicine Plus Targeted Therapy Maintenance in Advanced Pulmonary Adenocarcinoma

Anlotinib Hydrochloride Combined With EGFR TKIs in Advanced Non-small Cell Lung Cancer

RCTACSCNSCLC

Phase I Study of the Combination of Anlotinib With Gefitinib

CGMT

VICTORY-J

High Dose Gefitinib for the Treatment of Carcinomatous Meningitis in Adult Patients With Non-Small Cell Lung Cancer and Known or Suspected EGFR Mutations

NeoIntercal

The Continuation of Gefitinib Treatment Beyond Progression in Non-small Cell Lung Cancer Patients With EGFR Mutation

Intercalating and Maintenance Gefitinib in Combination With Chemotherapy for Advanced EGFR-mutant NSCLC

EGFR-TKI Concurrent With/Without WBRT in Brain Metastasis From NSCLC

Gefitinib, Docetaxel, and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer

Bone Metastasis on the Survival of Gefitinib Effective Patients

β-elemene Combine With EGFR-TKI for Advanced EGFR-TKI-resistant NSCLC

Phase 2 Study Of Neoadjuvant Iressa Treatment In Stage 1 NSCLC

Phase II Study of Docetaxel + ZD1839 in Elderly Patients With Non-Small Cell Lung Cancer

Phase III Trial to Evaluate the Elortinib vs Gefitinib in Advanced NSCLC With EGFR Exon 19 or 21 Mutations

Benefit

Apatinib Combine With EGFR-TKI for Advanced EGFR-TKI-resistant Non-Small Cell Lung Cancer

ISCAN

EGFR-TKI With/Without Chemotherapy in NSCLC Patients With Both EGFR Mutation and BIM Deletion Polymorphism

Gefitinib With or Without Carboplatin and Paclitaxel in Treating Older Patients With Unresectable or Metastatic Non-Small Cell Lung Cancer

Radiotherapy Combined With Thymosin for Metastatic NSCLC Patients Who Showed Stable Disease After First Line TKI Therapy

Chemotherapy Plus Gefitinib for Advanced Lung Adenocarcinoma and Sensitive EGFR Mutations: a Randomized Controlled Trial

Gefitinib Combined With Chemotherapy or Antiangiogensis in Patients With Bim Deletion or Low EGFR Mutation Abundance

EGFR-TKI With Chemotherapy in NSCLC Patients With Both EGFR Mutation and BIM Deletion Polymorphism